Technion Research & Development Foundation Ltd

Teva Pharmaceutical Industries Limited

Tirtsah Berger-Paskin

Jeffrey Sterling

Ruth Levy

Haim Yellin

David Lerner

John P Finberg

Moussa B Youdim

Alex Veinberg

Mussa B Youdim

The subject invention relates to pharmaceutical composition of R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof.

Pharmaceutical compositions of the R-enantiomer of N-propargyl

This invention relates to the use of R(+)-N-propargyl-1-aminoindan.

Use of the R-enantiomers of N-propargyl-1-aminoindan compounds for the

The subject invention provides R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing same. The subject invention also provides methods of treating a subject afflicted with Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an affective illness, a neurodegenerative disease, a neurotoxic injury, brain ischemia, a head trauma injury, a spinal trauma injury, schizophrenia, an attention deficit disorder, multiple sclerosis, or withdrawal symptoms, using R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt of the subject invention. The subject invention further provides a method of preventing nerve damage in a subject. Finally, the subject invention provides methods of preparing R(+)-N-propargyl-1-aminoindan, a salt thereof, and racemic N-propargyl-1-aminoindan.

R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses

R(+)-N-propargyl-1-aminoindan, its preparation and use and pharmaceutical compositions containing it. The novel compound was found to be useful for the treatment of human patients for Parkinson's disease, memory disorders, dementia of the Alzheimer type (DAT), depression and the hyperactive syndrome.

R-enantiomers of N-propargyl-aminoindan compounds, their preparation and

R(+)-N-p-opargyl-1-aminoindan, its preparation and use and pharmaceutical compositions containing it. The novel compound was found to be useful for the treatment of human patients for Parkinson's disease, memory disorders, dementia of the Alzheimer type (DAT), depression and the hyperactive syndrome.

Growing community of inventors

Raanana, Israel

Tirtsah Berger-Paskin